Summary
The largest cohort study on Covid-19 reported from Italy showed that the overall Vaccine Effectiveness (VE) against any SARS-CoV-2 infection waned from 71% 1 month after the second dose to 43% after 4 months and 24% after 6 months, especially in the elderly aged 70+.The lower vaccine coverage among social disadvantaged subgroups suggests the need of targeted communication and interventions. The odds of developing new-onset type 1 diabetes mellitus significantly increased in patients with Covid-19 diagnosis compared to those without Covid-19. American Indian/Alaskan Natives, Asian or Pacific Islanders, and Black populations are disproportionately at risk. In patients with pre-existing type 1 diabetes mellitus, the risk of developing diabetic ketoacidosis is significantly increased following Covid-19 diagnosis. The risk of developing ketoacidosis for those with Covid-19 was significantly higher than those without Covid-19, and the largest risk was among patients with higher Elixhauser Comorbidity Index. The National Cancer Institute has established the SARS-CoV-2 Serological Sciences Network to study coronavirus disease 2019. The SeroNet consortium comprises 49 institutions to study individuals with cancer, autoimmune disease, inflammatory bowel diseases, cardiovascular diseases, human immunodeficiency virus, transplant recipients, as well as otherwise healthy pregnant women, children, college students, and high-risk occupational workers.To support integrative data analyses across SeroNet studies, efforts are underway to define common data elements for standardized serology measurements, cellular and molecular assays, self-reported data, treatment, and clinical outcomes.The overarching framework for SeroNet epidemiology studies, critical research questions under investigation, and data accessibility for the worldwide scientific community are discussed. The rate ratio for a stage II presentation of testicular germ cell tumours decreased significantly during the pandemic but differences were observed for secondary outcomes.A study of 2528 healthcare workers in Saudi Arabia found 10.8% were seropositive for SARS-CoV-2 IgG antibodies. Of 185 retested after 2-3 months, 165 remained positive. Of 112 retested after 6 months, 44 remained positive. Respiratory therapists and hypertensive healthcare workers were more likely to be seropositive. Most seropositive healthcare workers reported prior Covid-19 symptoms, especially loss of smell. Non-smokers, non-Saudis, and those PCR-positive were more likely seropositive.
Mechanical ventilation requirement, older age, male sex, higher comorbidity, and hospital admission during the epidemic peak increased the risk of mortality. The median ICU stay was 10 days with a 35% mortality rate.
Published By:
Izabel Marcilio - PLoS ONE
2022
Cited By:
2
A study of Scotland's largest sexual health service found lower chlamydia testing but similar diagnoses rates compared to pre-pandemic, highlighting need for greater access where clinics closed.
Published By:
R. Holt - Abstracts
2022
Cited By:
0
ABSTRACT Background The waning of the protective effect of COVID-19 vaccines and timing of booster doses are debated. Methods Population-based cohort study in the largest Health-Authority of Lazio region, Italy, on 946,156 residents aged 12+ (study period: 1 January 2021–10 January 2022). VE against any SARS-CoV-2 infection (symptomatic or asymptomatic) was estimated through multivariable negative-binomial models using unvaccinated person-time as a reference.Results The primary vaccination cycle was completed by 81% of residents; of these, 45% received a booster dose.Overall, VE waned from 71% (CI 70–73%) 1 month after the second dose to 43% (CI 41–45%) after 4 months and 24% (CI 21–27%) after 6 months, especially in the elderly aged 70+.We observed a prompt restore of VE 15–19 days after the booster dose (69%, CI 67–70%).Our results support the recommendation of a booster dose 4 months after completion of the primary cycle, giving priority to elderly and fragile individuals.The lower vaccine coverage among social disadvantaged subgroups suggests the need of targeted communication and interventions.
Published By:
V. Fano - Expert Review of Vaccines
2022
Cited By:
1
We analyzed data from 50 US centers including 398,579 adults with cancer, of whom 63,413 (15.9%) were COVID-19 positive. COVID-19 positivity was associated with a 20% higher risk of death overall. Among COVID-19-positive patients, being age ≥ 65 years, male, from the Southern or Western US,having a high comorbidity score (≥ 4), hematologic cancer, multiple tumor sites, or recent chemotherapy were associated with higher mortality risk. Recent immunotherapy or targeted therapy were not. Using a large, nationally representative cancer patient cohort, we found factors linked to higher death risk from COVID-19 in those with cancer. The data may further insights into COVID-19's impact on cancer outcomes and ability to continue specific cancer treatments.
Published By:
N. Sharafeldin - Journal of Clinical Oncology
2021
Cited By:
82
Testicular cancer patients in Alberta, Canada had more advanced stage diagnoses during versus before the COVID-19 pandemic.
Published By:
R. Lee-Ying - CMAJ Open
2022
Cited By:
1
A registry analysis of German insurance claim data showed the overall cancer incidence decreased by 23% from 2017-2019 to 2020-2021.
Published By:
J. Diers - Cancer Communications
2022
Cited By:
3
Patients with cancer had a higher risk of breakthrough COVID-19 infection.Vaccination reduced risk especially for mRNA-1273 vaccine, and hematologic malignancies.
Published By:
Qianqian Song - Journal of Clinical Oncology
2022
Cited By:
57
The National Cancer Institute launched a network to study SARS-CoV-2.49 institutions study individuals with various conditions and target underrepresented groups; data will inform future responses.
Published By:
J. Figueiredo - Open Forum Infectious Diseases
2022
Cited By:
3
A study of 2528 healthcare workers found 10.8% tested positive for COVID-19 antibodies. Of 112 retested after 6 months, 44 remained positive.
Published By:
Faisal Alasmari - PLoS ONE
2022
Cited By:
1